Prism Medico & Pharmacy Ltd Hits New 52-Week High of Rs.30.22

Stock Performance and Recent Trading Activity

On 2 March 2026, Prism Medico & Pharmacy Ltd opened with a gap up, gaining 4.97% to reach an intraday high of Rs.30.22, the highest level recorded in the last 52 weeks. The stock’s intraday low was Rs.27.36, reflecting a symmetrical range of price movement during the session. Despite closing the day with a decline of 4.97% from its peak, the stock remains well above its key moving averages, trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This technical positioning indicates sustained upward momentum over multiple timeframes.

Notably, the stock experienced nine consecutive days of gains prior to the recent pullback, highlighting a strong trend reversal that propelled it from its 52-week low of Rs.11.62 to the current high. Over the past year, Prism Medico & Pharmacy Ltd has delivered a robust total return of 67.03%, significantly outperforming the Sensex’s 9.34% gain over the same period.

Sector and Market Context

The NBFC sector, to which Prism Medico & Pharmacy Ltd belongs, has witnessed mixed performance amid broader market volatility. On the day Prism Medico reached its new high, the Sensex opened sharply lower by 2,743.46 points but recovered 1,473.46 points to trade at 80,017.19, still down 1.56% overall. The Sensex remains below its 50-day moving average, although the 50-day average itself is positioned above the 200-day moving average, signalling a cautious but potentially stabilising market environment.

Within this context, Prism Medico’s outperformance is notable. The stock’s ability to sustain gains and break through resistance levels reflects underlying strength relative to both its sector and the broader market indices. However, it is important to note that the stock underperformed its sector by 4.12% on the day it hit the new high, indicating some short-term profit-taking or volatility despite the longer-term upward trend.

Mojo Score and Rating Update

Prism Medico & Pharmacy Ltd currently holds a Mojo Score of 46.0, which corresponds to a Mojo Grade of Sell. This represents a downgrade from its previous Hold rating, effective from 17 November 2025. The downgrade reflects a reassessment of the stock’s risk and reward profile despite its recent price appreciation. The company’s Market Cap Grade stands at 4, indicating a mid-tier market capitalisation within its sector.

Technical Indicators and Moving Averages

The stock’s position above all major moving averages is a key technical indicator supporting the recent rally. Trading above the 200-day moving average is often viewed as a sign of long-term strength, while the 5-day and 20-day averages reflect short-term momentum. The convergence of these averages below the current price level suggests that the stock has established a solid base for its upward trajectory.

However, the recent day’s trading session saw a reversal after nine consecutive days of gains, with the stock closing lower than its intraday high. This pullback may represent a natural consolidation phase following a sustained rally, allowing the stock to digest gains before potentially establishing new support levels.

Comparative Performance Over One Year

Over the last 12 months, Prism Medico & Pharmacy Ltd’s stock price has surged by 67.03%, a performance that significantly outpaces the Sensex’s 9.34% increase. This outperformance highlights the stock’s ability to generate returns well above the broader market benchmark, underscoring its relative strength within the NBFC sector. The 52-week low of Rs.11.62 serves as a stark contrast to the current high, emphasising the scale of the rally.

Summary of Key Metrics

To summarise, Prism Medico & Pharmacy Ltd’s stock performance is characterised by:

• A new 52-week high of Rs.30.22 reached on 2 March 2026
• A year-to-date gain of 67.03%, outperforming the Sensex by nearly 58 percentage points
• Trading above all major moving averages, signalling strong technical momentum
• A recent downgrade in Mojo Grade from Hold to Sell, reflecting a cautious stance on valuation and risk
• Market capitalisation grade of 4, indicating a mid-sized company within its sector

Despite the recent pullback after a prolonged rally, the stock’s ability to sustain levels above key technical thresholds and its significant outperformance relative to the broader market remain noteworthy. The new 52-week high marks a milestone that reflects both the company’s resilience and the evolving dynamics within the NBFC sector.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →